Taysha gene therapies announces regenerative medicine advanced therapy (rmat) designation granted by u.s. fda for tsha-102 in rett syndrome

Rmat designation follows fda's review of available safety and efficacy data from the first three patients dosed with the low dose of tsha-102 across both reveal phase 1/2 trials (adolescent/adult and pediatric)

TSHA Ratings Summary

TSHA Quant Ranking